Troponin-I and left ventricular function in pediatric high-risk acute lymphoblastic leukemia after daunorubicin treatment
Abstract
Background Daunorubicin is a chemotherapy drug for leukemia treatment, but it can cause cardiotoxicity. When heart damage occurs, myocardial sarcomeres release troponin-I, which could potentially be useful as a cardiotoxicity biomarker.
Objective To assess for possible correlations between troponin-I and echocardiographic parameters of left ventricular function after administration of daunorubicin in children with high-risk acute lymphoblastic leukemia (ALL).
Methods This cross-sectional study on 37 children with high-risk ALL was performed from July 2017 to December 2018, in Padang, West Sumatera. The left ventricular systolic function parameters measured were ejection fraction (EF) and fractional shortening (FS); the left ventricular diastolic function parameter was E/A ratio. Troponin-I measurements and echocardiography were performed after daunorubicin treatment at the end of induction phase chemotherapy. Pearson’s correlation test was used to analyze for a correlation between troponin-I and echocardiographic parameters.
Results Subjects had a mean age of 6.27 (SD 4.43) years, and males comprised 56.8%. Subjects’ mean troponin-I concentration was 5.49 (SD 0.86) ng/mL, and mean EF, FS, and E/A values were 65 (SD 5) %, 36 (SD 4) %, and 1.52 (SD 0.56), respectively. Troponin-I was not significantly correlated with EF (r=0.062; P=0.715) or FS (r=0.309; P=0.172). However, there was a weak, significant negative correlation between troponin-I and E/A ratio
(r=-0.383; P=0.019).
Conclusion Troponin-I level has no significant correlations with the echocardiographic parameters of left ventricular systolic function. However, there is a weak significant negative correlation between troponin-I level and the left ventricular diastolic parameter of E/A ratio.
References
2. Lipshultz SE, Karnik R, Sambatakos P, Franco VI, Ross SM, Miller TL. Anthracycline-related cardiotoxicity in childhood cancer survivors. Curr Opin Cardiol. 2014;29:103-12. DOI: 10.1097/HCO.0000000000000034.
3. Volkova M, Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7:214-20. DOI: 10.2174/157340311799960645.
4. Corremans R, Adao R, DeKeulenaer GW, Leite-Moreira, Bras-Silva C. Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. Clin Exp Pharmacol Physiol. 2019;46:204-15. DOI: 10.1111/1440-1681.13036.
5. Siahaan HI, Tobing TC, Rosdiana N, Lubis B. Dampak kardiotoksik obat kemoterapi golongan antrasiklin. Sari Pediatri. 2007;9:151-6. DOI: 10.14238/sp9.2.2007.151-6.
6. Shaikh AS, Saleem AF, Mohsin SS, Alam MM, Ahmed MA. Anthracycline-induced cardiotoxicity : Prospective cohort study from Pakistan. BMJ Open. 2013;3:e003663. DOI: 10.1111/1440-1681.13036.
7. Bu'Lock FA, Mott GM, Oakhill A, Martin EP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J. 1995;73:340-50. DOI: 10.1136/hrt.73.4.340.
8. Salgado AA, Filho CDC, Reis CASS. The role of echocardiography in chemotherapy. Arq Bras Cardiol:imagem cardiovasc. 2014;27:18-23. DOI: 10.5935/2318-8219.20140004.
9. Oztarhan K, Guler S, Aktas B, Arslan M, Salsioglu Z, Aydogan G. The value of echocardiography versus cardiac troponin-I levels in the early detection of anthracycline cardiotoxicity in childhood acute leukemia: prospective evaluation of a 7-year-long clinical follow-up. Pediatr Hematol Oncol. 2011;28:380-94. DOI: 10.3109/08880018.2011.563772.
10. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis. 2010;53:121-9. DOI: 10.1016/j.pcad.2010.04.002.
11. Muller-Bardorff M, Hallermayer K, Schroder A, Ebert C, Borgya A, Gerhardt W, et al. Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation. Clin Chem. 1997;43:458-66. DOI: 10.1093/clinchem/43.3.458
12. Bertinchant JP, Polge A, Juan JM, Oliva-Lauraire MC, Giuliana I, Marty-Double C, et al. Evaluation of cardiac troponin-I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin Chim Acta. 2003;329:39-51. DOI: 10.1016/s0009-8981(03)00013-5
13. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122–31. DOI: 10.1016/j.jacc.2009.02.050
14. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin-I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749-54. DOI: 10.1161/01.CIR.0000130926.51766.CC .
15. Unit Koordinasi Kerja Hematologi-Onkologi IDAI. Protokol pengobatan leukemia limpoblastik akut anak tahun 2013 (Indonesian Childhood ALL-2013 Protocol). Jakarta: UKK Hematologi-Onkologi IDAI 2013. p 1-29.
16. Katruka IA. Human cardiac troponin complex. Structure and functions. Biochemistry. 2013;78:1447-65. DOI: 10.1134/S0006297913130063
17. Mertens LL, Friedberg MK. Systolic ventricular function. In: Lai WW, Mertens LL, Cohen MS, Geva T, editors. Echocardiography in pediatric and congenital heart disease. Oxford: John Wiley&Sons Ltd; 2016. p. 96-131.
18. Park KM. Pediatric cardiology for practitioners. 5th ed. Philadelphia: Elsevier; 2008. p. 65-113.
19. Brunner M, Moeslinger T, Spieckerman PG. Echocardiography for teaching cardiac physiology in practical student courses. Am J Physiol. 1995;268:1-9. DOI: 10.1152/advances.1995.268.6.S2
20. Mertens LL, Friedberg MK. Echocardiographic assessment of cardiac dimensions, cardiac function and valve function. In: Allen HD, Driscoll DJ, Shaddy RE, Feltes TF, editors. Moss and Adam’s heart disease in infants, children and adolescents including the fetus and young adult. 8th ed. Philadelphia: Lippincott Williams & Wilkins;2012. p.172-206.
21. Sukardi R. Penatalaksanaan terkini gagal jantung pada anak. In: Putra ST, Djer MM, Roeslani RD, Endryarni B, Yuniar I, editors. Management of pediatric heart disease for practitioners: from early detection to intervention. Jakarta: Departemen Ilmu Kesehatan Anak FKUI-RSCM; 2000. p. 40-63.
22. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314. DOI: 10.1016/j.echo.2016.01.011
23. Kossaify A, Nasr A. Diastolic dysfunction and the new recommendations for echocardiographic assessment of left ventricular diastolic function: Summary of guidelines and novelties in diagnosis and grading. JDMS. 2019;35:317-25. DOI: 10.1177/8756479319836781.
24. Sari TT, Windiastuti E, Cempako GR, Devaera Y. Prognosis leukemia limfoblastik akut pada anak obes. Sari Pediatri. 2010;12:58-62. DOI: 10.14238/sp12.1.2010.58-62.
25. Wa’u DV, Mulatsih S, Murni IK. Profil jantung pasien akut limfoblastik leukemia anak yang mendapatkan terapi anthracycline. Indones J Cancer. 2017;11:15-20. DOI: 10.33371/ijoc.v11i1.496.
26. Wijayanti LP, Supriyadi E. Faktor prognostic dan kesintasan pasien leukemia limfoblastik akut anak di RSUP Dr. Sardjito, Yogyakarta, 2010-2015. Indones J Cancer. 2017;11:145-50. DOI: 10.33371/ijoc.v11i4.532.
27. Ariawati K, Windiastuti E, Gatot D. Toksisitas kemoterapi leukemia limfoblastik akut pada fase induksi dan profilaksis susunan saraf pusat dengan metotreksat 1 gram. Sari Pediatri. 2007;9:257-8. DOI: 10.14238/sp9.4.2007.252-8.
28. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol. 2008;130:688-95. DOI: 10.1309/AJCPB66LRIIVMQDR.
29. Shafi A, Siddiqui N, Imtiaz S, Sajid MUD. Left ventricular systolic dysfunction predicted by early troponin-I release after anthracycline based chemotherapy in breast cancer patients. J Ayub Med Coll Abbottabad. 2017;29:266-9.
30. Raj S, Franco VI, Lipshultz SE. Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis and treatment. Curr Treat Options Cardiovasc Med. 2014;16:315. DOI: 10.1007/s11936-014-0315-4.
31. Bertinchant JP, Polge A, Juan JM, Oliva-Lauraire MC, Giuliani I, Marty-Double C, et al. Evaluation of cardiac troponin-I and T levels as markers of myocardial damage in doxorubicine-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin Chim Acta. 2003;329:39-51. DOI: 10.1016/S0009-8981(03)00013-5.
32. Handojo K, Sjakti HA, Yanuarso PB, Akib AAP. Fungsi sistolik dan diastolic jantung pada pasien anak dengan osteosarcoma yang mendapat terapi doksorubicin di RS Cipto Mangunkusumo. Sari Pediatri. 2014;16:149-56. DOI: 10.14238/sp16.3.2014.149-56.
33. Rahman MA. Fungsi sistolik dan diastolik ventrikel kiri pada anak dengan leukemia limfoblastik akut pasca terapi daunorubicin. Sari Pediatri. 2005;7:160-8. DOI: 10.14238/sp7.3.2005.160-8.
34. Mele D, Nardozza M, Spallarossa P, Frassoldati A, Tocchetti CG, Cadeddu C, et al. Current views on anthracycline cardiotoxicity. Heart Fail Rev. 2016;21:621-34. DOI: 10.1007/s10741-016-9564-5.
35. Sandri MT, Cardinale D, Zorzino L, Passerini R, Lentati P, Martinoni A, et al. Minor increases in plasma troponin-I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem. 2003;49:248-52. DOI: 10.1373/49.2.248.
36. Leandro J, Dyck J, Poppe D, Shore R, Airhart C, Greenburg M, et al. Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol. 1994;74:1152-6. DOI: 10.1016/0002-9149(94)90470-7.
37. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin-I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36:517-22. DOI: 10.1016/S0735-1097(00)00748-8.
38. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schaffer EM, Schwartz RG, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children Cancer Study Group. Pediatrics. 1992;89:942-9. PMID: 1579408.
39. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107-33. DOI: 10.1016/j.echo.2016.01.011.
40. Hutchison S. Principles of echocardiography and intracardiac echocardiography. Philadelphia: Elsevier Saunders; 2012. p.253-69.
41. Schmitt K, Tulzer G, Merl M, Aichhorn A, Grillenberger A, Wiesinger G, et al. Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: diastolic versus systolic parameters. Eur J Pediatr. 1995;154:201-4. DOI: 10.1007/BF01954271.
42. Dorup I, Levitt G, Sullivan I, Sorensen K. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function. Heart. 2004;90:1214-6. DOI: 10.1136/hrt.2003.027516.
Copyright (c) 2021 Rinche Annur, Didiko Hariyant, Amirah Zatil Izzah
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2021-03-16
Published 2021-03-16
